Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
Identifieur interne : 001278 ( PubMed/Checkpoint ); précédent : 001277; suivant : 001279Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
Auteurs : Miyuki Kawase [Japon] ; Kazuya Shirato ; Lia Van Der Hoek ; Fumihiro Taguchi ; Shutoku MatsuyamaSource :
- Journal of virology [ 1098-5514 ] ; 2012.
Descripteurs français
- KwdFr :
- Bronches (cytologie), Bronches (virologie), Cellules épithéliales (), Cellules épithéliales (virologie), Humains, Inhibiteurs de la cystéine protéinase (pharmacologie), Inhibiteurs de la sérine protéinase (pharmacologie), Pénétration virale (), Régulation négative (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- cytologie : Bronches.
- pharmacologie : Inhibiteurs de la cystéine protéinase, Inhibiteurs de la sérine protéinase.
- physiologie : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- virologie : Bronches, Cellules épithéliales, Syndrome respiratoire aigu sévère.
- Cellules épithéliales, Humains, Pénétration virale, Régulation négative, Virus du SRAS.
English descriptors
- KwdEn :
- Bronchi (cytology), Bronchi (virology), Cysteine Proteinase Inhibitors (pharmacology), Down-Regulation (drug effects), Epithelial Cells (drug effects), Epithelial Cells (virology), Humans, SARS Virus (drug effects), SARS Virus (physiology), Serine Proteinase Inhibitors (pharmacology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Virus Internalization (drug effects).
- MESH :
- chemical , pharmacology : Cysteine Proteinase Inhibitors, Serine Proteinase Inhibitors.
- cytology : Bronchi.
- drug effects : Down-Regulation, Epithelial Cells, SARS Virus, Virus Internalization.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- virology : Bronchi, Epithelial Cells, Severe Acute Respiratory Syndrome.
- Humans.
Abstract
The type II transmembrane protease TMPRSS2 activates the spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) on the cell surface following receptor binding during viral entry into cells. In the absence of TMPRSS2, SARS-CoV achieves cell entry via an endosomal pathway in which cathepsin L may play an important role, i.e., the activation of spike protein fusogenicity. This study shows that a commercial serine protease inhibitor (camostat) partially blocked infection by SARS-CoV and human coronavirus NL63 (HCoV-NL63) in HeLa cells expressing the receptor angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. Simultaneous treatment of the cells with camostat and EST [(23,25)trans-epoxysuccinyl-L-leucylamindo-3-methylbutane ethyl ester], a cathepsin inhibitor, efficiently prevented both cell entry and the multistep growth of SARS-CoV in human Calu-3 airway epithelial cells. This efficient inhibition could be attributed to the dual blockade of entry from the cell surface and through the endosomal pathway. These observations suggest camostat as a candidate antiviral drug to prevent or depress TMPRSS2-dependent infection by SARS-CoV.
DOI: 10.1128/JVI.00094-12
PubMed: 22496216
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22496216Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.</title><author><name sortKey="Kawase, Miyuki" sort="Kawase, Miyuki" uniqKey="Kawase M" first="Miyuki" last="Kawase">Miyuki Kawase</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name></author><author><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Matsuyama, Shutoku" sort="Matsuyama, Shutoku" uniqKey="Matsuyama S" first="Shutoku" last="Matsuyama">Shutoku Matsuyama</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22496216</idno><idno type="pmid">22496216</idno><idno type="doi">10.1128/JVI.00094-12</idno><idno type="wicri:Area/PubMed/Corpus">001376</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001376</idno><idno type="wicri:Area/PubMed/Curation">001376</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001376</idno><idno type="wicri:Area/PubMed/Checkpoint">001278</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001278</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.</title><author><name sortKey="Kawase, Miyuki" sort="Kawase, Miyuki" uniqKey="Kawase M" first="Miyuki" last="Kawase">Miyuki Kawase</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name></author><author><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Matsuyama, Shutoku" sort="Matsuyama, Shutoku" uniqKey="Matsuyama S" first="Shutoku" last="Matsuyama">Shutoku Matsuyama</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bronchi (cytology)</term><term>Bronchi (virology)</term><term>Cysteine Proteinase Inhibitors (pharmacology)</term><term>Down-Regulation (drug effects)</term><term>Epithelial Cells (drug effects)</term><term>Epithelial Cells (virology)</term><term>Humans</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Serine Proteinase Inhibitors (pharmacology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Bronches (cytologie)</term><term>Bronches (virologie)</term><term>Cellules épithéliales ()</term><term>Cellules épithéliales (virologie)</term><term>Humains</term><term>Inhibiteurs de la cystéine protéinase (pharmacologie)</term><term>Inhibiteurs de la sérine protéinase (pharmacologie)</term><term>Pénétration virale ()</term><term>Régulation négative ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Cysteine Proteinase Inhibitors</term><term>Serine Proteinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Bronches</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Bronchi</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Down-Regulation</term><term>Epithelial Cells</term><term>SARS Virus</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de la cystéine protéinase</term><term>Inhibiteurs de la sérine protéinase</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Bronches</term><term>Cellules épithéliales</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bronchi</term><term>Epithelial Cells</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules épithéliales</term><term>Humains</term><term>Pénétration virale</term><term>Régulation négative</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The type II transmembrane protease TMPRSS2 activates the spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) on the cell surface following receptor binding during viral entry into cells. In the absence of TMPRSS2, SARS-CoV achieves cell entry via an endosomal pathway in which cathepsin L may play an important role, i.e., the activation of spike protein fusogenicity. This study shows that a commercial serine protease inhibitor (camostat) partially blocked infection by SARS-CoV and human coronavirus NL63 (HCoV-NL63) in HeLa cells expressing the receptor angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. Simultaneous treatment of the cells with camostat and EST [(23,25)trans-epoxysuccinyl-L-leucylamindo-3-methylbutane ethyl ester], a cathepsin inhibitor, efficiently prevented both cell entry and the multistep growth of SARS-CoV in human Calu-3 airway epithelial cells. This efficient inhibition could be attributed to the dual blockade of entry from the cell surface and through the endosomal pathway. These observations suggest camostat as a candidate antiviral drug to prevent or depress TMPRSS2-dependent infection by SARS-CoV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22496216</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>12</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.</ArticleTitle><Pagination><MedlinePgn>6537-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00094-12</ELocationID><Abstract><AbstractText>The type II transmembrane protease TMPRSS2 activates the spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) on the cell surface following receptor binding during viral entry into cells. In the absence of TMPRSS2, SARS-CoV achieves cell entry via an endosomal pathway in which cathepsin L may play an important role, i.e., the activation of spike protein fusogenicity. This study shows that a commercial serine protease inhibitor (camostat) partially blocked infection by SARS-CoV and human coronavirus NL63 (HCoV-NL63) in HeLa cells expressing the receptor angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. Simultaneous treatment of the cells with camostat and EST [(23,25)trans-epoxysuccinyl-L-leucylamindo-3-methylbutane ethyl ester], a cathepsin inhibitor, efficiently prevented both cell entry and the multistep growth of SARS-CoV in human Calu-3 airway epithelial cells. This efficient inhibition could be attributed to the dual blockade of entry from the cell surface and through the endosomal pathway. These observations suggest camostat as a candidate antiviral drug to prevent or depress TMPRSS2-dependent infection by SARS-CoV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawase</LastName><ForeName>Miyuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirato</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>van der Hoek</LastName><ForeName>Lia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Fumihiro</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Matsuyama</LastName><ForeName>Shutoku</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015842">Serine Proteinase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015842" MajorTopicYN="N">Serine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22496216</ArticleId><ArticleId IdType="pii">JVI.00094-12</ArticleId><ArticleId IdType="doi">10.1128/JVI.00094-12</ArticleId><ArticleId IdType="pmc">PMC3393535</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2009 Nov;83(21):11133-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19706706</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Mol Med. 2009 Jul;15(7):303-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19581128</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(11):e7870</Citation><ArticleIdList><ArticleId IdType="pubmed">19924243</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(1):e8729</Citation><ArticleIdList><ArticleId IdType="pubmed">20090954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 May;84(10):5089-96</Citation><ArticleIdList><ArticleId IdType="pubmed">20219906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Jun;84(11):5605-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20237084</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Jul 23;285(30):22758-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20507992</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2010 Sep;20(5):298-310</Citation><ArticleIdList><ArticleId IdType="pubmed">20629046</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Oct;84(19):10016-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20631123</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Dec;84(24):12658-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20926566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Jan;85(2):873-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21068237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Feb;85(4):1554-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21123387</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 May;85(9):4122-34</Citation><ArticleIdList><ArticleId IdType="pubmed">21325420</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2011 May 10;413(2):265-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21435673</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Aug;85(15):7872-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21613395</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Dec;85(24):13363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21994442</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2003 Jul;200(3):282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12845623</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2004 Jul;203(3):740-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15221932</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 1997 Sep 15;44(3):309-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9325052</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 Aug;86(Pt 8):2269-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16033974</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12543-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16116101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">16339146</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Oct;80(19):9896-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16973594</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol Hepatol. 2008 Jan;23(1):34-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17995943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Sep;82(17):8887-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18562523</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Sep;82(17):8942-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18562527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Dec;82(23):11985-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18786990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jan;83(2):712-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18971274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Apr;83(7):3200-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19158246</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19321428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 May 1;137(3):433-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19410541</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 23;27(45):6324-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19840668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><noCountry><name sortKey="Matsuyama, Shutoku" sort="Matsuyama, Shutoku" uniqKey="Matsuyama S" first="Shutoku" last="Matsuyama">Shutoku Matsuyama</name><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name></noCountry><country name="Japon"><region name="Région de Kantō"><name sortKey="Kawase, Miyuki" sort="Kawase, Miyuki" uniqKey="Kawase M" first="Miyuki" last="Kawase">Miyuki Kawase</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001278 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001278 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22496216
|texte= Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22496216" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |